Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2

Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting

Read more at globenewswire.com